Dr. Gourlay joined Actinogen in December 2020 as Chief Medical Officer and was appointed as CEO and Managing Director in March 2021. He has more than 30 years’ experience in the development of novel therapeutics and has significant regulatory experience interacting with the FDA and EMA. Formerly the founding Chief Medical Officer at US-based Principia Biopharma Inc., Dr Gourlay was responsible for the supervision of first-in-human, Phase 2 and 3 clinical trial programs for four small molecules in orphan immunological diseases, multiple sclerosis and cancer. The data generated by these trials, and Dr Gourlay’s roadshow presentations, supported a successful NASDAQ IPO of Principia Biopharma Inc. in 2018 and its subsequent acquisition.
Prior to Principia Biopharma, Dr Gourlay was a Partner at GBS Venture Partners, where he was instrumental in the development and exit of multiple clinical stage therapeutic companies. Before GBS, he held positions of increasing responsibility at Genentech, Inc. in the areas of pharmacoepidemiology and early clinical development.
Dr Gourlay holds a Bachelor of Medicine, Bachelor of Surgery (MB,BS) from the University of Melbourne, a PhD in Medicine from Monash University, an MBA from Macquarie University and is a fellow of the Royal Australian College of Physicians. He is a specialist physician in general internal medicine.